Nurexone Biologic Inc
F:J90
Nurexone Biologic Inc
Total Current Assets
Nurexone Biologic Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Total Current Assets
$2.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
146%
|
CAGR 10-Years
33%
|
|
|
Enerflex Ltd
TSX:EFX
|
Total Current Assets
CA$992m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Total Current Assets
CA$583.9m
|
CAGR 3-Years
22%
|
CAGR 5-Years
30%
|
CAGR 10-Years
21%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Total Current Assets
CA$1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Total Current Assets
CA$643m
|
CAGR 3-Years
4%
|
CAGR 5-Years
25%
|
CAGR 10-Years
12%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Total Current Assets
$907.6k
|
CAGR 3-Years
-45%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Total Current Assets?
Total Current Assets
2.7m
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Total Current Assets amounts to 2.7m USD.
What is Nurexone Biologic Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
33%
Over the last year, the Total Current Assets growth was 0%. The average annual Total Current Assets growth rates for Nurexone Biologic Inc have been 17% over the past three years , 146% over the past five years , and 33% over the past ten years .
